<DOC>
	<DOCNO>NCT02288325</DOCNO>
	<brief_summary>This study evaluate efficacy , safety tolerability levomilnacipran extended-release ( ER ) compare placebo prevention depression relapse ( MDD ) .</brief_summary>
	<brief_title>A Multicenter , Relapse Prevention Study With Levomilnacipran ER Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Milnacipran</mesh_term>
	<criteria>Men Women 1870 Currently meet DSMV criterion Major Depressive Disorder ( MDD ) The patient must ongoing major depressive episode least 8 week 18 month The patient must least 3 lifetime episode MDD ( include current episode ) Women pregnant , woman breastfeed study , woman childbearing potential practicing reliable method birth control Patients consider suicide risk History nonresponse 2 antidepressant ( adequate treatment ) Patients history meet The Diagnostic Statistical Manual Mental Disorders , Fifth Edition ( DSM5 ) criterion manic , hypomanic , mixed episode schizophrenia psychotic disorder obsessivecompulsive disorder Panic disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Fetzima</keyword>
	<keyword>Relapse-prevention</keyword>
	<keyword>Placebo-controlled</keyword>
</DOC>